Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to cre... Frequency Therapeutics Inc is a clinical-stage biotechnology company focused on harnessing the body's innate biology to repair or reverse damage caused by degenerative diseases. Its Progenitor Cell Activation approach uses combinations of molecules to activate progenitor cells within the body to create functional tissue. Its product candidate FX-322 is being developed for treating sensorineural hearing loss. 더 보기
KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to advance additional pipeline...
CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.87 | -10.1868912872 | 37.99 | 39.16 | 33 | 63922 | 35.30575326 | CS |
4 | -7.58 | -18.1774580336 | 41.7 | 43.31 | 33 | 90220 | 37.50902732 | CS |
12 | -34.78 | -50.4789550073 | 68.9 | 75 | 33 | 109387 | 45.2964344 | CS |
26 | -12.38 | -26.623655914 | 46.5 | 98 | 30.719 | 107173 | 51.69245063 | CS |
52 | -14.63 | -30.0102564103 | 48.75 | 98 | 30.005 | 76873 | 51.71045711 | CS |
156 | 21.12 | 162.461538462 | 13 | 98 | 13 | 72996 | 50.85058491 | CS |
260 | 21.12 | 162.461538462 | 13 | 98 | 13 | 72996 | 50.85058491 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관